Use Of Fragmin In Hemodialysis

Pfizer

Status and phase: Completed; Phase 3

Conditions: Chronic Renal Failure

Treatments: Drug: Fragmin

Study type: Interventional

Funder types: Industry

Identifiers

NCT01879618

A6301091

Details and patient eligibility

About

The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.

Enrollment: 152 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• chronic renal failure on hemodialysis

Exclusion criteria

• significant comorbidities that would prevent a patient from completing the trial

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

152 participants in 1 patient group

Fragmin

Experimental group

Description:

Fragmin given according to the flexible dosing regimen outlined in the protocol

Treatment:

Drug: Fragmin